Subscribe To
Ecb lagarde - underlying inflation is still strong, wage growth is “historically high”
European Central Bank president Christine Lagarde spoke over the weekend, saying underlying inflation in the eurozone is still strong and wage growth ...
October 15, 2023, 8:40 pm
New zealand shifts right as christopher luxon named prime minister
Keep an eye on the New Zealand dollar at the weekly open.In general, G7 elections aren't a big deal in the FX market, particularly in a place as stabl...
October 15, 2023, 5:44 pm
Carmot therapeutics highlights clinical data from its pipeline of treatments for obesity and diabetes at obesityweek®
– CT-388 administered once-weekly resulted in clinically meaningful weight loss and insulin sensitivity over a 4 week treatment period in participan...
October 15, 2023, 4:00 pm
The 3 most volatile stocks to steer clear of in q4
With market uncertainty being the name of the game, investors may want to red flag the most volatile stocks to avoid. Usually, securities that ...
October 15, 2023, 1:48 pm
Netflix is planning 'houses' where fans can get closer to their favorite shows
Netflix is planning to open two permanent locations in the US by 2025. Fans will be able to eat, drink, and shop at stores based on its most popular s...
October 15, 2023, 8:49 am
Watch: all video from europe’s largest bitcoin conference now available
Bitcoin Amsterdam concluded this week, but not without a number of notable headlines showcasing the technology as a frontier for innovation. Bitcoin A...
October 15, 2023, 7:29 am
Youtube surpasses netflix as top video platform for teens: survey
A new report from Piper Sandler finds YouTube (GOOGL, GOOG) has overtaken Netflix (NFLX) as the top daily video platform for teens. The research shows...
October 15, 2023, 6:00 am
Assertio holdings: uncovering a tapestry of trading opportunities from this oversold ticker
Assertio Holdings has undergone a significant transformation in its business model, reducing debt and exiting the opioid business. The company's recen...
October 15, 2023, 4:41 am
Equities mixed after consumer sentiment survey, bank earnings
US benchmark equity indexes were struggling for direction ahead of Friday’s close as traders weighed a survey showing a jump in consumers’ inflati...
October 15, 2023, 3:29 am
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm